FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012562524> ?p ?o ?g. }

• W2012562524 endingPage "96" @default.
• W2012562524 startingPage "86" @default.
• W2012562524 abstract "Herpes simplex virus thymidine kinase (HSVTK) with ganciclovir (GCV) is currently the most widely used suicide gene/prodrug system in cancer gene therapy. A major limitation in this therapy is the inefficient activation of GCV by HSVTK to its active antimetabolites. We described earlier two strategies to overcome this limitation: (1) generation of HSVTK mutants with improved GCV activation potential and (2) construction of a fusion protein encoding HSVTK and mouse guanylate kinase (MGMK), the second enzyme in the GCV activation pathway. As a means to further enhance GCV activation, two MGMK/HSVTK constructs containing the HSVTK mutants, mutant 30 and SR39, were generated and evaluated for their tumor and bystander killing effects in vitro and in vivo. One fusion mutant, MGMK/30, shows significant reduction in IC(50) values of approximately 12 500-fold, 100-fold, and 125-fold compared with HSVTK, mutant 30 or MGMK/HSVTK, respectively. In vitro bystander analyses show that 5% of MGMK/30-expressing cells are sufficient to induce 75% of tumor cell killing. In an xenograft tumor model, MGMK/30 displays the greatest inhibition of tumor growth at a GCV concentration (1 mg kg(-1)) that has no effect on wild-type HSVTK-, MGMK/HSVTK-, or mutant 30-transfected cells. Another fusion construct, MGMK/SR39, sensitizes rat C6 glioma cells to GCV by 2500-fold or 25-fold compared with HSVTK or MGMK/HSVTK, respectively. In vitro analyses show similar IC(50) values between cells harboring SR39 and MGMK/SR39, although MGMK/SR39 seems to elicit stronger bystander killing effects in which 1% of MGMK/SR39-transfected cells result in 60% cell death. In a xenograft tumor model, despite observable tumor growth inhibition, no statistical significance in tumor volume was detected between mice harboring SR39- and MGMK/SR39-transfected cells when dosed with 1 mg kg(-1) GCV. However, at a lower dose of GCV (0.1 mg kg(-1)), MGMK/SR39 seems to have slightly greater tumor growth inhibition properties compared with SR39 (P< or =0.05). In vivo studies indicate that both mutant fusion proteins display substantial improvements in bystander killing in the presence of 1 mg kg(-1) GCV, even when only 5% of the tumor cells are transfected. Such fusion mutants with exceptional prodrug converting properties will allow administration of lower and non-myelosuppressive doses of GCV concomitant with improved tumor killing and as such are promising candidates for translational gene therapy studies." @default.
• W2012562524 created "2016-06-24" @default.
• W2012562524 creator A5012977063 @default.
• W2012562524 creator A5070711653 @default.
• W2012562524 creator A5074905192 @default.
• W2012562524 date "2009-09-18" @default.
• W2012562524 modified "2023-10-07" @default.
• W2012562524 title "Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo" @default.
• W2012562524 cites W1492885137 @default.
• W2012562524 cites W1531398313 @default.
• W2012562524 cites W1580979140 @default.
• W2012562524 cites W1966538775 @default.
• W2012562524 cites W1974484551 @default.
• W2012562524 cites W1988450448 @default.
• W2012562524 cites W1992307792 @default.
• W2012562524 cites W1992322591 @default.
• W2012562524 cites W2002553384 @default.
• W2012562524 cites W2016138321 @default.
• W2012562524 cites W2024938749 @default.
• W2012562524 cites W2035032239 @default.
• W2012562524 cites W2054590955 @default.
• W2012562524 cites W2064169769 @default.
• W2012562524 cites W2077462718 @default.
• W2012562524 cites W2094053329 @default.
• W2012562524 cites W2095109478 @default.
• W2012562524 cites W2100310330 @default.
• W2012562524 cites W2113911127 @default.
• W2012562524 cites W2312790198 @default.
• W2012562524 cites W2321167123 @default.
• W2012562524 cites W2611745499 @default.
• W2012562524 doi "https://doi.org/10.1038/cgt.2009.60" @default.
• W2012562524 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2808426" @default.
• W2012562524 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19763147" @default.
• W2012562524 hasPublicationYear "2009" @default.
• W2012562524 type Work @default.
• W2012562524 sameAs 2012562524 @default.
• W2012562524 citedByCount "29" @default.
• W2012562524 countsByYear W20125625242012 @default.
• W2012562524 countsByYear W20125625242013 @default.
• W2012562524 countsByYear W20125625242014 @default.
• W2012562524 countsByYear W20125625242015 @default.
• W2012562524 countsByYear W20125625242016 @default.
• W2012562524 countsByYear W20125625242017 @default.
• W2012562524 countsByYear W20125625242018 @default.
• W2012562524 countsByYear W20125625242019 @default.
• W2012562524 countsByYear W20125625242021 @default.
• W2012562524 countsByYear W20125625242022 @default.
• W2012562524 crossrefType "journal-article" @default.
• W2012562524 hasAuthorship W2012562524A5012977063 @default.
• W2012562524 hasAuthorship W2012562524A5070711653 @default.
• W2012562524 hasAuthorship W2012562524A5074905192 @default.
• W2012562524 hasBestOaLocation W20125625241 @default.
• W2012562524 hasConcept C104317684 @default.
• W2012562524 hasConcept C108215921 @default.
• W2012562524 hasConcept C111599444 @default.
• W2012562524 hasConcept C111829193 @default.
• W2012562524 hasConcept C143065580 @default.
• W2012562524 hasConcept C153911025 @default.
• W2012562524 hasConcept C159047783 @default.
• W2012562524 hasConcept C184235292 @default.
• W2012562524 hasConcept C185592680 @default.
• W2012562524 hasConcept C19106626 @default.
• W2012562524 hasConcept C202751555 @default.
• W2012562524 hasConcept C203014093 @default.
• W2012562524 hasConcept C207001950 @default.
• W2012562524 hasConcept C2522874641 @default.
• W2012562524 hasConcept C2776147627 @default.
• W2012562524 hasConcept C2781196997 @default.
• W2012562524 hasConcept C34981463 @default.
• W2012562524 hasConcept C54355233 @default.
• W2012562524 hasConcept C55493867 @default.
• W2012562524 hasConcept C86803240 @default.
• W2012562524 hasConcept C98274493 @default.
• W2012562524 hasConceptScore W2012562524C104317684 @default.
• W2012562524 hasConceptScore W2012562524C108215921 @default.
• W2012562524 hasConceptScore W2012562524C111599444 @default.
• W2012562524 hasConceptScore W2012562524C111829193 @default.
• W2012562524 hasConceptScore W2012562524C143065580 @default.
• W2012562524 hasConceptScore W2012562524C153911025 @default.
• W2012562524 hasConceptScore W2012562524C159047783 @default.
• W2012562524 hasConceptScore W2012562524C184235292 @default.
• W2012562524 hasConceptScore W2012562524C185592680 @default.
• W2012562524 hasConceptScore W2012562524C19106626 @default.
• W2012562524 hasConceptScore W2012562524C202751555 @default.
• W2012562524 hasConceptScore W2012562524C203014093 @default.
• W2012562524 hasConceptScore W2012562524C207001950 @default.
• W2012562524 hasConceptScore W2012562524C2522874641 @default.
• W2012562524 hasConceptScore W2012562524C2776147627 @default.
• W2012562524 hasConceptScore W2012562524C2781196997 @default.
• W2012562524 hasConceptScore W2012562524C34981463 @default.
• W2012562524 hasConceptScore W2012562524C54355233 @default.
• W2012562524 hasConceptScore W2012562524C55493867 @default.
• W2012562524 hasConceptScore W2012562524C86803240 @default.
• W2012562524 hasConceptScore W2012562524C98274493 @default.
• W2012562524 hasIssue "2" @default.
• W2012562524 hasLocation W20125625241 @default.
• W2012562524 hasLocation W20125625242 @default.
• W2012562524 hasLocation W20125625243 @default.

• next